| Prof Michael Good AO |
| Griffith University |
| Rheumatic Heart Disease and Streptococcus A infections |
| Vaccine |
Key outcomes:
- Development collaboration with major pharmaceutical company and anticipated commercialisation through Australian NewCo establishment in 2023/2024
- Currently in Phase 1 clinical trial overseas
- Investment from industry
- Leveraged $3.5m from the Heart Foundation
- Leveraged over $750,000 of funding from external sources including Lowitja, Snow Foundation etc.
- $550,000 in funding and over $500,000 in kind to fund a Phase 1 clinical trial from the Li Ka Shing Institute (Canada)
“NFMRI funding for our streptococcal vaccine project has provided critical leverage to enable us to secure funds for the clinical aspects of our Phase I trial, which would not have been possible without the ability to produce GMP-grade vaccine and to undertake formal toxicology studies on the vaccine. If the vaccine is successful, then much credit will be owing to NFMRI and their willingness to help us through this important phase in vaccine development”